NBB - No argument from me, yet other posters are saying no more road shows. Focusing on get the trial completed seems to be the route they are taking. 

The epigenetics business just got a huge boost of exposure this morning when Crispr Therapeutics (CRSP) got the go-ahead from the European regulators this morning for their DNA-splicing therapy for blood disorder beta thalassaemia. "We will look back and think that this is the real beginning of gene therapy," said Prof. Robin Lovell-Badge of London's Francis Crick Institute.

This could be the start of many more articles about epigenetics. If that happens it will now be time for the masses to be educated about the differences in the epigenetic technologies. Helping the press get it write will give us the greatest exposure. That is most often done by conference calls and in person at industry conferences. My vote is for them to continue their road shows.

tada